Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.

Q32 Bio (QTTB) announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart, or ADX-914, which identified encouraging clinical activity in patients ...

MetaVia (MTVA) announced positive top-line 16-week results from the two-part Phase 2a clinical trial in patients with presumed metabolic dysfunction-associated steatohepatitis, or MASH.

Each of the two parts of the Phase 2a trial of DA-1241 were designed ... For more information on this clinical trial, please visit: www.clinicaltrials.gov NCT06054815. About DA-1241 DA-1241 ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks InflaRx ( (IFRX) ) has issued an update.

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from ...

Topline data from the chronic cohort is expected in Q2 2025Institutional Review Board (IRB) protocol amendment changes ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Each of the two parts of the Phase 2a trial of DA-1241 were designed to ... Furthermore, in Phase 1a and 1b trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM.